<p>Elanco Animal Health（纽约证券交易所代码：ELAN - 获取免费报告）在周四发布的一份报告中，摩根大通的股票研究人员将其目标价格从 28.00 美元上调至 30.00 美元，Benzinga 报道。该券商目前对该股票给予 “增持” 评级。摩根大通的目标价格表明，相较于公司之前的收盘价，存在 25.03% 的潜在上涨空间。</p>
<p>获取 <strong>Elanco Animal Health</strong> 的提醒：</p>
<ul>
<li>看涨还是看跌？评估动物健康护理股票</li>
</ul>
<p>其他一些研究分析师最近也对该公司发布了报告。花旗集团在 4 月 15 日的报告中开始覆盖 Elanco Animal Health。他们对该股票设定了 “买入” 评级和 30.00 美元的目标价格。KeyCorp 在 2 月 25 日的报告中将 Elanco Animal Health 的目标价格从 27.00 美元上调至 29.00 美元，并给予该公司 “增持” 评级。Weiss Ratings 在 4 月 27 日的报告中将 Elanco Animal Health 的评级从 “卖出（d）” 上调至 “卖出（d+）”。瑞银集团在 3 月 10 日的研究报告中重申了对 Elanco Animal Health 股票的 “买入” 评级。最后，Piper Sandler 在 1 月 22 日的研究报告中将 Elanco Animal Health 的评级从 “中性” 上调至 “增持”，并将其目标价格从 24.00 美元上调至 30.00 美元。一位股票研究分析师给予该股票 “强烈买入” 评级，九位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价格为 28.10 美元。</p>
<p><strong>阅读我们关于 Elanco Animal Health 的最新研究报告</strong></p>
<h2>Elanco Animal Health 股票下跌 8.3%</h2>
<ul>
<li>Zoetis 宣布新股息，暗示被低估</li>
</ul>
<p>在周四的交易时段，NYSE:ELAN 下跌 2.19 美元，达到 24.00 美元。该公司交易了 8,155,888 股，相较于其平均交易量 5,021,183 股。该公司的 50 日移动平均价格为 23.85 美元，200 日移动平均价格为 23.33 美元。该股票的市值为 119.3 亿美元，市盈率为-50.20，市盈增长比率为 2.93，贝塔值为 1.69。Elanco Animal Health 的 1 年最低价为 11.83 美元，1 年最高价为 27.72 美元。该公司的流动比率为 2.17，速动比率为 1.08，债务与股本比率为 0.60。</p>
<p>Elanco Animal Health（纽约证券交易所代码：ELAN - 获取免费报告）最后一次公布季度财报是在 5 月 6 日。该公司报告本季度每股收益（EPS）为 0.40 美元，超出分析师一致预期的 0.34 美元，超出幅度为 0.06 美元。该公司本季度的收入为 13.7 亿美元，而一致预期为 12.8 亿美元。Elanco Animal Health 的股本回报率为 7.16%，净利润率为-4.92%。该公司的季度收入同比增长 14.9%。在去年同期，该公司每股收益为 0.37 美元。Elanco Animal Health 已将其 2026 年第二季度的指导目标设定为 0.250-0.285 EPS，2026 财年的指导目标设定为 1.030-1.090 EPS。分析师预测 Elanco Animal Health 在当前年度的每股收益为 1.03 美元。</p>
<h2>对 Elanco Animal Health 的对冲基金看法</h2>
<ul>
<li>2 只具有重大上涨潜力的逆向股票选择</li>
</ul>
<p>对冲基金最近对该公司的持仓进行了调整。瑞银集团在第三季度将其在 Elanco Animal Health 的持股增加了 56.7%。瑞银集团目前拥有 16,468,148 股该公司股票，价值 331,669,000 美元，此前在上个季度又购买了 5,961,457 股。T. Rowe Price Investment Management Inc.在第四季度将其在 Elanco Animal Health 的持股增加了 11.8%。T. Rowe Price Investment Management Inc.目前拥有 35,227,418 股该公司股票，价值 797,197,000 美元，此前在上个季度又购买了 3,717,404 股。Invesco Ltd.在第四季度将其在 Elanco Animal Health 的持股增加了 336.0%。Invesco Ltd.目前拥有 4,789,037 股该公司股票，价值 108,376,000 美元，此前在上个季度又购买了 3,690,735 股。Allspring Global Investments Holdings LLC 在第一季度购买了 Elanco Animal Health 的新头寸，价值约 66,390,000 美元。最后，Artemis Investment Management LLP 在第四季度购买了 Elanco Animal Health 的新头寸，价值约 55,693,000 美元。机构投资者持有该公司 97.48% 的股票。</p>
<h2>影响 Elanco Animal Health 的关键故事</h2>
<p>以下是本周影响 Elanco Animal Health 的关键新闻故事：</p>
<ul>
<li>积极情绪：季度业绩超预期 — Elanco 报告 Q1 调整后每股收益为 $0.40（对比 $0.34 的市场预期），收入为 $13.71 亿美元（同比增长 15%；有机增长 10%），调整后 EBITDA 为 $3.34 亿美元，利润率改善。这些结果验证了公司的创新驱动增长。Elanco Animal Health 报告 2026 年第一季度业绩</li>
<li>积极情绪：上调全年目标 — Elanco 上调了 2026 财年的指引（收入目标为 $50.10 亿至 $50.85 亿，调整后 EBITDA 为 $9.75 亿至 $10.05 亿，调整后每股收益为 $1.03 至 $1.09），并将创新收入目标提高至 $12 亿；管理层还收紧了年末净杠杆目标至 ~3.0–3.2 倍。这些提升支持未来的盈利增长。Elanco Animal Health 报告 2026 年第一季度业绩</li>
<li>积极情绪：监管/产品势头 — 公司宣布了 Negasunt Powder 和 Tanidil 的紧急使用授权，支持近期的产品收入和投资者重视的管道证明点。Elanco Animal Health 在盈利强劲和产品势头下上涨</li>
<li>中性情绪：盈利材料可用 — 完整的盈利电话会议记录和投资者演示文稿/幻灯片已发布（对细分市场、地理和利润驱动因素的详细信息很有用）。Elanco 2026 年第一季度盈利电话会议记录 Q1 结果 - 盈利电话会议演示</li>
<li>消极情绪：Q2 指引略低于市场预期 — Elanco 指引 Q2 每股收益为 $0.250–$0.285，而市场预期接近 $0.29（收入大致持平）。中间值的失误可能削弱了近期的预期，并导致在反弹后出现获利回吐。Elanco Animal Health 报告 2026 年第一季度业绩</li>
</ul>
<h2>关于 Elanco Animal Health</h2>
<p>(获取免费报告)</p>
<p>Elanco Animal Health Inc 是全球动物健康领域的领导者，致力于改善食品和伴侣动物的福祉。该公司开发、制造和销售一系列产品，包括寄生虫药、疫苗、抗生素和饲料添加剂，旨在预防和治疗家畜和宠物的疾病。Elanco 的产品组合涵盖了食品生产动物——如牛、猪、家禽和水产养殖——以及伴侣动物，提供支持寄生虫控制、疼痛管理和传染病预防的产品。</p>
<p>Elanco 最初成立于 20 世纪中期，作为礼来公司（Eli Lilly and Company）的动物健康部门，2018 年独立成为一家上市公司。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 Elanco Animal Health</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Elanco Animal Health 吗？</h2>
<p>在你考虑 Elanco Animal Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Elanco Animal Health 并不在名单上。</p>
<p>虽然 Elanco Animal Health 目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ELAN

<p>摩根大通已将 Elanco Animal Health（纽约证券交易所代码：ELAN）的目标股价从 28.00 美元上调至 30.00 美元，维持 “增持” 评级。这个新目标暗示相较于前一交易日收盘价有 25.03% 的潜在上涨空间。其他分析师也给予了积极评级，平均评级为 “适度买入”，目标股价为 28.10 美元。尽管 Elanco 最近公布了强劲的季度财报，显示每股收益为 0.40 美元，超出预期，但其股价最近交易下跌至 24.00 美元。机构投资者持有该公司 97.48% 的股份</p>

<p>Elanco Animal Health (NYSE:ELAN - Get Free Report) had its price target increased by equities researchers at JPMorgan Chase &amp; Co. from $28.00 to $30.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s price target indicates a potential upside of 25.03% from the company's previous close.</p>
<div class="lb-trans"><p>Elanco Animal Health（纽约证券交易所代码：ELAN - 获取免费报告）在周四发布的一份报告中，摩根大通的股票研究人员将其目标价格从 28.00 美元上调至 30.00 美元，Benzinga 报道。该券商目前对该股票给予 “增持” 评级。摩根大通的目标价格表明，相较于公司之前的收盘价，存在 25.03% 的潜在上涨空间。</p>
</div><p>Get <strong>Elanco Animal Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Elanco Animal Health</strong> 的提醒：</p>
</div><ul>
<li>Bullish or Bearish? Vetting Animal Health Care Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>看涨还是看跌？评估动物健康护理股票</li>
</ul>
</div><p>A number of other research analysts also recently issued reports on the company. Citigroup initiated coverage on Elanco Animal Health in a report on Wednesday, April 15th. They set a &#34;buy&#34; rating and a $30.00 price target on the stock. KeyCorp increased their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, February 25th. Weiss Ratings raised Elanco Animal Health from a &#34;sell (d)&#34; rating to a &#34;sell (d+)&#34; rating in a report on Monday, April 27th. UBS Group restated a &#34;buy&#34; rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, Piper Sandler upgraded Elanco Animal Health from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and upped their price target for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $28.10.</p>
<div class="lb-trans"><p>其他一些研究分析师最近也对该公司发布了报告。花旗集团在 4 月 15 日的报告中开始覆盖 Elanco Animal Health。他们对该股票设定了 “买入” 评级和 30.00 美元的目标价格。KeyCorp 在 2 月 25 日的报告中将 Elanco Animal Health 的目标价格从 27.00 美元上调至 29.00 美元，并给予该公司 “增持” 评级。Weiss Ratings 在 4 月 27 日的报告中将 Elanco Animal Health 的评级从 “卖出（d）” 上调至 “卖出（d+）”。瑞银集团在 3 月 10 日的研究报告中重申了对 Elanco Animal Health 股票的 “买入” 评级。最后，Piper Sandler 在 1 月 22 日的研究报告中将 Elanco Animal Health 的评级从 “中性” 上调至 “增持”，并将其目标价格从 24.00 美元上调至 30.00 美元。一位股票研究分析师给予该股票 “强烈买入” 评级，九位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价格为 28.10 美元。</p>
</div><p><strong>Read Our Latest Research Report on Elanco Animal Health</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Elanco Animal Health 的最新研究报告</strong></p>
</div><h2>Elanco Animal Health Stock Down 8.3%</h2>
<div class="lb-trans"><h2>Elanco Animal Health 股票下跌 8.3%</h2>
</div><ul>
<li>Zoetis Declares New Dividend, Hinting At Undervaluation</li>
</ul>
<div class="lb-trans"><ul>
<li>Zoetis 宣布新股息，暗示被低估</li>
</ul>
</div><p>NYSE:ELAN traded down $2.19 during trading hours on Thursday, reaching $24.00. 8,155,888 shares of the company traded hands, compared to its average volume of 5,021,183. The business's 50-day moving average price is $23.85 and its two-hundred day moving average price is $23.33. The stock has a market capitalization of $11.93 billion, a P/E ratio of -50.20, a P/E/G ratio of 2.93 and a beta of 1.69. Elanco Animal Health has a 1 year low of $11.83 and a 1 year high of $27.72. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60.</p>
<div class="lb-trans"><p>在周四的交易时段，NYSE:ELAN 下跌 2.19 美元，达到 24.00 美元。该公司交易了 8,155,888 股，相较于其平均交易量 5,021,183 股。该公司的 50 日移动平均价格为 23.85 美元，200 日移动平均价格为 23.33 美元。该股票的市值为 119.3 亿美元，市盈率为-50.20，市盈增长比率为 2.93，贝塔值为 1.69。Elanco Animal Health 的 1 年最低价为 11.83 美元，1 年最高价为 27.72 美元。该公司的流动比率为 2.17，速动比率为 1.08，债务与股本比率为 0.60。</p>
</div><p>Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.06. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company's quarterly revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts predict that Elanco Animal Health will post 1.03 earnings per share for the current year.</p>
<div class="lb-trans"><p>Elanco Animal Health（纽约证券交易所代码：ELAN - 获取免费报告）最后一次公布季度财报是在 5 月 6 日。该公司报告本季度每股收益（EPS）为 0.40 美元，超出分析师一致预期的 0.34 美元，超出幅度为 0.06 美元。该公司本季度的收入为 13.7 亿美元，而一致预期为 12.8 亿美元。Elanco Animal Health 的股本回报率为 7.16%，净利润率为-4.92%。该公司的季度收入同比增长 14.9%。在去年同期，该公司每股收益为 0.37 美元。Elanco Animal Health 已将其 2026 年第二季度的指导目标设定为 0.250-0.285 EPS，2026 财年的指导目标设定为 1.030-1.090 EPS。分析师预测 Elanco Animal Health 在当前年度的每股收益为 1.03 美元。</p>
</div><h2>Hedge Funds Weigh In On Elanco Animal Health</h2>
<div class="lb-trans"><h2>对 Elanco Animal Health 的对冲基金看法</h2>
</div><ul>
<li>2 Contrarian Stock Picks With Major Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只具有重大上涨潜力的逆向股票选择</li>
</ul>
</div><p>Hedge funds have recently made changes to their positions in the business. UBS Group AG boosted its stake in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company's stock valued at $331,669,000 after buying an additional 5,961,457 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company's stock valued at $797,197,000 after buying an additional 3,717,404 shares during the last quarter. Invesco Ltd. boosted its stake in Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company's stock valued at $108,376,000 after buying an additional 3,690,735 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Elanco Animal Health during the first quarter valued at approximately $66,390,000. Finally, Artemis Investment Management LLP bought a new position in Elanco Animal Health during the fourth quarter valued at approximately $55,693,000. Institutional investors own 97.48% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。瑞银集团在第三季度将其在 Elanco Animal Health 的持股增加了 56.7%。瑞银集团目前拥有 16,468,148 股该公司股票，价值 331,669,000 美元，此前在上个季度又购买了 5,961,457 股。T. Rowe Price Investment Management Inc.在第四季度将其在 Elanco Animal Health 的持股增加了 11.8%。T. Rowe Price Investment Management Inc.目前拥有 35,227,418 股该公司股票，价值 797,197,000 美元，此前在上个季度又购买了 3,717,404 股。Invesco Ltd.在第四季度将其在 Elanco Animal Health 的持股增加了 336.0%。Invesco Ltd.目前拥有 4,789,037 股该公司股票，价值 108,376,000 美元，此前在上个季度又购买了 3,690,735 股。Allspring Global Investments Holdings LLC 在第一季度购买了 Elanco Animal Health 的新头寸，价值约 66,390,000 美元。最后，Artemis Investment Management LLP 在第四季度购买了 Elanco Animal Health 的新头寸，价值约 55,693,000 美元。机构投资者持有该公司 97.48% 的股票。</p>
</div><h2>Key Stories Impacting Elanco Animal Health</h2>
<div class="lb-trans"><h2>影响 Elanco Animal Health 的关键故事</h2>
</div><p>Here are the key news stories impacting Elanco Animal Health this week:</p>
<div class="lb-trans"><p>以下是本周影响 Elanco Animal Health 的关键新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Quarterly beat — Elanco reported Q1 adjusted EPS of $0.40 (vs. $0.34 consensus) and revenue of $1.371B (+15% YoY; 10% organic), with adjusted EBITDA of $334M and improving margins. These results validate the company’s innovation-led growth. Elanco Animal Health Reports First Quarter 2026 Results</li>
<li>Positive Sentiment: Upgraded full-year targets — Elanco raised FY2026 guidance (revenue to $5.010B–$5.085B, adjusted EBITDA to $975M–$1,005M, adjusted EPS to $1.03–$1.09) and raised its innovation revenue target to $1.2B; management also tightened year-end net leverage goals to ~3.0–3.2x. These lifts are supportive of forward earnings growth. Elanco Animal Health Reports First Quarter 2026 Results</li>
<li>Positive Sentiment: Regulatory/product momentum — The company announced emergency use authorizations for Negasunt Powder and Tanidil, supporting near-term product revenue and pipeline proof points that investors value. Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum</li>
<li>Neutral Sentiment: Earnings materials available — Full earnings call transcript and the investor presentation/slide deck were released (useful for details on segments, geography and margin drivers). Elanco Q1 2026 Earnings Call TranscriptQ1 Results - Earnings Call Presentation</li>
<li>Negative Sentiment: Q2 guide slightly soft vs. consensus — Elanco guided Q2 EPS to $0.250–$0.285 vs. a consensus near $0.29 (revenues roughly in line). That miss on the midpoint may have trimmed near-term expectations and contributed to profit-taking after the rally. Elanco Animal Health Reports First Quarter 2026 Results</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：季度业绩超预期 — Elanco 报告 Q1 调整后每股收益为 $0.40（对比 $0.34 的市场预期），收入为 $13.71 亿美元（同比增长 15%；有机增长 10%），调整后 EBITDA 为 $3.34 亿美元，利润率改善。这些结果验证了公司的创新驱动增长。Elanco Animal Health 报告 2026 年第一季度业绩</li>
<li>积极情绪：上调全年目标 — Elanco 上调了 2026 财年的指引（收入目标为 $50.10 亿至 $50.85 亿，调整后 EBITDA 为 $9.75 亿至 $10.05 亿，调整后每股收益为 $1.03 至 $1.09），并将创新收入目标提高至 $12 亿；管理层还收紧了年末净杠杆目标至 ~3.0–3.2 倍。这些提升支持未来的盈利增长。Elanco Animal Health 报告 2026 年第一季度业绩</li>
<li>积极情绪：监管/产品势头 — 公司宣布了 Negasunt Powder 和 Tanidil 的紧急使用授权，支持近期的产品收入和投资者重视的管道证明点。Elanco Animal Health 在盈利强劲和产品势头下上涨</li>
<li>中性情绪：盈利材料可用 — 完整的盈利电话会议记录和投资者演示文稿/幻灯片已发布（对细分市场、地理和利润驱动因素的详细信息很有用）。Elanco 2026 年第一季度盈利电话会议记录 Q1 结果 - 盈利电话会议演示</li>
<li>消极情绪：Q2 指引略低于市场预期 — Elanco 指引 Q2 每股收益为 $0.250–$0.285，而市场预期接近 $0.29（收入大致持平）。中间值的失误可能削弱了近期的预期，并导致在反弹后出现获利回吐。Elanco Animal Health 报告 2026 年第一季度业绩</li>
</ul>
</div><h2>About Elanco Animal Health</h2>
<div class="lb-trans"><h2>关于 Elanco Animal Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.</p>
<div class="lb-trans"><p>Elanco Animal Health Inc 是全球动物健康领域的领导者，致力于改善食品和伴侣动物的福祉。该公司开发、制造和销售一系列产品，包括寄生虫药、疫苗、抗生素和饲料添加剂，旨在预防和治疗家畜和宠物的疾病。Elanco 的产品组合涵盖了食品生产动物——如牛、猪、家禽和水产养殖——以及伴侣动物，提供支持寄生虫控制、疼痛管理和传染病预防的产品。</p>
</div><p>Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.</p>
<div class="lb-trans"><p>Elanco 最初成立于 20 世纪中期，作为礼来公司（Eli Lilly and Company）的动物健康部门，2018 年独立成为一家上市公司。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Elanco Animal Health</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Elanco Animal Health</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=ELAN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Elanco Animal Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Elanco Animal Health 吗？</h2>
</div><p>Before you consider Elanco Animal Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Elanco Animal Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Elanco Animal Health 并不在名单上。</p>
</div><p>While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Elanco Animal Health 目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Elanco Animal Health (NYSE:ELAN) Given New $30.00 Price Target at JPMorgan Chase & Co.

Market Beat

Elanco Animal Health

摩根大通

花旗

科凯国际

瑞银集团

Piper Sandler Cos

硕腾

普信金融

景顺投资管理

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

摩根大通给予 Elanco Animal Health（纽约证券交易所代码：ELAN）新的目标价为 30.00 美元